Medically refractory neurosarcoidosis treated with infliximab

Intern Med J. 2011 Apr;41(4):354-7. doi: 10.1111/j.1445-5994.2011.02457.x.

Abstract

Neurosarcoidosis can worsen despite standard immunosuppressive therapy, a situation for which there is no established medical management. We present three cases of medically refractory neurosarcoidosis treated with infliximab. All three patients showed a clinical response to this treatment and side effects were limited. A summary of reported cases of neurosarcoidosis treated with infliximab is included. This case series supports a role for infliximab in the treatment of patients with medically refractory neurosarcoidosis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage*
  • Central Nervous System Diseases / diagnosis*
  • Central Nervous System Diseases / drug therapy*
  • Central Nervous System Diseases / immunology
  • Drug Administration Schedule
  • Drug Resistance / drug effects
  • Drug Resistance / immunology
  • Female
  • Follow-Up Studies
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Infliximab
  • Male
  • Sarcoidosis / diagnosis*
  • Sarcoidosis / drug therapy*
  • Sarcoidosis / immunology
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha* / immunology

Substances

  • Antibodies, Monoclonal
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab

Supplementary concepts

  • Neurosarcoidosis